207 related articles for article (PubMed ID: 18037967)
1. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.
Hurst CD; Tomlinson DC; Williams SV; Platt FM; Knowles MA
Oncogene; 2008 Apr; 27(19):2716-27. PubMed ID: 18037967
[TBL] [Abstract][Full Text] [Related]
2. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer.
Oeggerli M; Schraml P; Ruiz C; Bloch M; Novotny H; Mirlacher M; Sauter G; Simon R
Oncogene; 2006 Oct; 25(49):6538-43. PubMed ID: 16953223
[TBL] [Abstract][Full Text] [Related]
3. 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer.
Shen H; Morrison CD; Zhang J; Underwood W; Yang N; Frangou C; Eng K; Head K; Bollag RJ; Kavuri SK; Rojiani AM; Li Y; Yan L; Hill A; Woloszynska-Read A; Wang J; Liu S; Trump DL; Candace JS
Oncotarget; 2013 Nov; 4(11):2124-34. PubMed ID: 24231253
[TBL] [Abstract][Full Text] [Related]
4. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells.
Olsson AY; Feber A; Edwards S; Te Poele R; Giddings I; Merson S; Cooper CS
Oncogene; 2007 Feb; 26(7):1028-37. PubMed ID: 16909110
[TBL] [Abstract][Full Text] [Related]
5. Amplification and overexpression of E2F3 in human bladder cancer.
Feber A; Clark J; Goodwin G; Dodson AR; Smith PH; Fletcher A; Edwards S; Flohr P; Falconer A; Roe T; Kovacs G; Dennis N; Fisher C; Wooster R; Huddart R; Foster CS; Cooper CS
Oncogene; 2004 Feb; 23(8):1627-30. PubMed ID: 14716298
[TBL] [Abstract][Full Text] [Related]
6. [miR-503-5p inhibits the proliferation of T24 and EJ bladder cancer cells by interfering with the Rb/E2F signaling pathway].
Li X; Han X; Yang J; Sun J; Wei P
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Oct; 33(10):1360-1364. PubMed ID: 29169421
[TBL] [Abstract][Full Text] [Related]
7. Rb knockdown accelerates bladder cancer progression through E2F3 activation.
Wang JP; Jiao Y; Wang CY; Xu ZB; Zhang B
Int J Oncol; 2017 Jan; 50(1):149-160. PubMed ID: 27922689
[TBL] [Abstract][Full Text] [Related]
8. Expression analysis of 6p22 genomic gain in retinoblastoma.
Orlic M; Spencer CE; Wang L; Gallie BL
Genes Chromosomes Cancer; 2006 Jan; 45(1):72-82. PubMed ID: 16180235
[TBL] [Abstract][Full Text] [Related]
9. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer.
Wu Q; Hoffmann MJ; Hartmann FH; Schulz WA
Mol Cancer; 2005 May; 4(1):16. PubMed ID: 15876350
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3.
Huang L; Luo J; Cai Q; Pan Q; Zeng H; Guo Z; Dong W; Huang J; Lin T
Int J Cancer; 2011 Apr; 128(8):1758-69. PubMed ID: 20549700
[TBL] [Abstract][Full Text] [Related]
11. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki67 index.
Wright C; Thomas D; Mellon K; Neal DE; Horne CH
Br J Urol; 1995 Feb; 75(2):173-9. PubMed ID: 7850321
[TBL] [Abstract][Full Text] [Related]
12. E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity.
Danielian PS; Friesenhahn LB; Faust AM; West JC; Caron AM; Bronson RT; Lees JA
Oncogene; 2008 Nov; 27(51):6561-70. PubMed ID: 18663357
[TBL] [Abstract][Full Text] [Related]
13. QKI-6 inhibits bladder cancer malignant behaviours through down-regulating E2F3 and NF-κB signalling.
Shi F; Deng Z; Zhou Z; Jiang CY; Zhao RZ; Sun F; Cui D; Bei XY; Yang BY; Sun Q; Wang XJ; Wu Q; Xia SJ; Han BM
J Cell Mol Med; 2019 Oct; 23(10):6578-6594. PubMed ID: 31449345
[TBL] [Abstract][Full Text] [Related]
14. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of potential target genes of the 6p22.3-amplicon in urinary bladder cancer].
Oeggerli M; Schraml P; Novotny H; Sauter G; Simon R
Verh Dtsch Ges Pathol; 2005; 89():219-24. PubMed ID: 18035695
[TBL] [Abstract][Full Text] [Related]
16. E2f3a and E2f3b contribute to the control of cell proliferation and mouse development.
Chong JL; Tsai SY; Sharma N; Opavsky R; Price R; Wu L; Fernandez SA; Leone G
Mol Cell Biol; 2009 Jan; 29(2):414-24. PubMed ID: 19015245
[TBL] [Abstract][Full Text] [Related]
17. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer.
Oeggerli M; Tomovska S; Schraml P; Calvano-Forte D; Schafroth S; Simon R; Gasser T; Mihatsch MJ; Sauter G
Oncogene; 2004 Jul; 23(33):5616-23. PubMed ID: 15122326
[TBL] [Abstract][Full Text] [Related]
18. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression.
Xu HJ; Cairns P; Hu SX; Knowles MA; Benedict WF
Int J Cancer; 1993 Mar; 53(5):781-4. PubMed ID: 8449603
[TBL] [Abstract][Full Text] [Related]
19. Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer.
Chatterjee SJ; George B; Goebell PJ; Alavi-Tafreshi M; Shi SR; Fung YK; Jones PA; Cordon-Cardo C; Datar RH; Cote RJ
J Pathol; 2004 Jul; 203(3):762-70. PubMed ID: 15221935
[TBL] [Abstract][Full Text] [Related]
20. E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.
Smith NL; Welcsh P; Press JZ; Agnew KJ; Garcia R; Swisher EM
Genes Chromosomes Cancer; 2012 Nov; 51(11):1054-62. PubMed ID: 22887716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
